---
schema_version: "secwatch.filing_event.v1"
accession: "0001293971-24-000010"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:40:01.985617+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# bluebird bio restates 2019-2023 financials due to lease accounting errors; going concern doubt reaffirmed

## Summary
- Restating financials for 2019-2022 annual and interim periods; lease assets/liabilities understated by $100-200M.
- Material weakness in internal controls over financial reporting; CEO and CFO conclude disclosure controls ineffective.
- Full-year 2023 revenue $29.5M (ZYNTEGLO $16.7M, SKYSONA $12.4M); cash position $275M at Dec 31, 2023.
- Entered up to $175M term loan with Hercules Capital; $75M drawn; cash runway expected through Q1 2026.
- 2024 guidance: 85-105 total patient starts; first LYFGENIA revenue expected in Q3 2024; gross-to-net discounts 20-25%.

## SEC filing metadata
- accession: 0001293971-24-000010
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/blue-20240324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001293971-24-000010
- JSON: https://secwatch.observer/filing/0001293971-24-000010.json
- Plain text: https://secwatch.observer/filing/0001293971-24-000010.txt

## Key facts
- Auditor Changes
  bluebird bio, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Ernst & Young LLP
  source text: of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon. The Company intends to restate its consolidated financial statements as of and for the year ended December 31, 2022 in connection with the filing of its 2023 Form 10-K. Similarly, the Company will include restated unaudited financial information for each of the first three quarters of 2023 and 2022 in its 2023 Form 10-K (each such annual and quarterly period to be restated, a “Restated Period”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm
- Earnings Releases
  bluebird bio, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 26, 2024, bluebird bio, Inc. (the “Company”) announced certain financial results for the three months and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm
- Earnings Releases
  bluebird bio, Inc. reported the twelve months ended December 31, 2023 results: revenue $29.5 million.
  - Period: the twelve months ended December 31, 2023
  - Revenue: $29.5 million
  - Result: reported results
  source text: Total revenue, net was $29.5 million for the twelve months ended December 31, 2023, compared to $3.6 million for the twelve months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm
- Earnings Releases
  bluebird bio, Inc. reported the three months ended December 31, 2023 results: revenue $7.8 million.
  - Period: the three months ended December 31, 2023
  - Revenue: $7.8 million
  - Result: reported results
  source text: Total revenue, net was $7.8 million for the three months ended December 31, 2023, compared to $0.1 million for the three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.